7Baggers

Xeris Pharmaceuticals Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Gross Profit  
 Operating Profit  
 Net Income  
20190331 20190630 20190930 20191231 20200331 20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 -50.79-36.63-22.47-8.315.842034.1648.32Milllion

Xeris Pharmaceuticals Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 
  revenue44,390,000 48,320,000 38,008,000 33,196,000 38,008,000 33,196,000 25,306,000 22,073,000 21,429,000 11,035,000 8,906,000 8,051,000 7,089,000 9,448,000 2,027,000 1,788,000 1,864,000 323,000 320,000 248,000 801,000 582,000 819,000 263,000 467,000 170,000 565,000 354,000 
  cost of revenue10,281,000 8,201,000 7,555,000 5,319,000 7,555,000 5,319,000 4,810,000 6,273,000 4,889,000 3,220,000 3,383,000 1,826,000 3,407,000 2,832,000 1,299,000 1,790,000 1,603,000 10,000 23,000 42,000 4,000 
  gross profit34,109,000 40,119,000 30,453,000 27,877,000 30,453,000 27,877,000 20,496,000 15,800,000 16,540,000 7,815,000 5,523,000 6,225,000 3,682,000 6,616,000 728,000 -2,000 261,000 313,000 297,000 248,000 801,000 582,000 819,000 221,000 467,000 170,000 561,000 354,000 
  operating expenses                            
  research and development6,382,000 5,034,000 6,087,000 4,838,000 6,087,000 4,838,000 3,718,000 6,250,000 10,082,000 5,663,000 5,383,000 4,032,000 5,110,000 3,876,000 5,289,000 6,646,000 12,420,000 15,518,000 19,333,000 13,167,000 12,390,000 10,875,000 8,677,000 8,712,000 6,578,000 5,725,000 4,201,000 3,662,000 
  sales, general and administrative                            
  total operating expenses43,950,000 42,321,000 46,432,000 41,154,000 46,432,000 41,154,000 39,412,000 44,874,000 64,811,000 32,173,000 31,310,000 22,965,000 23,025,000 20,360,000 22,933,000 28,252,000 33,062,000 30,395,000 34,357,000 25,685,000 21,115,000 15,525,000 13,176,000 11,951,000 9,676,000 7,742,000 5,760,000 5,003,000 
  operating income-9,841,000 -4,913,000 -15,979,000 -13,277,000 -15,979,000 -13,277,000 -18,916,000 -29,074,000 -48,271,000 -24,358,000 -25,787,000 -16,740,000 -19,343,000 -13,744,000 -22,205,000 -28,254,000 -32,801,000 -30,082,000 -34,060,000 -25,437,000 -20,314,000 -14,943,000 -12,357,000 -11,730,000 -9,209,000 -7,572,000 -5,199,000 -4,649,000 
  net income-13,390,000 -12,189,000 -19,842,000 -16,834,000 -19,842,000 -26,607,000 -26,185,000 -33,714,000 -50,790,000 -26,009,000 -27,515,000 -18,411,000 -21,857,000 -16,000,000 -24,099,000 -29,184,000 -33,082,000 -32,836,000 -34,385,000 -25,277,000 -20,419,000 -14,767,000 -12,987,000 -11,907,000 -9,146,000 -7,527,000 -5,232,000 -4,649,000 

We provide you with 20 years income statements for Xeris Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Xeris Pharmaceuticals stock. Explore the full financial landscape of Xeris Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Xeris Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.